Yarrow Bioscience (NASDAQ:YARW) Releases Quarterly Earnings Results

Yarrow Bioscience (NASDAQ:YARW) issued its quarterly earnings data on Thursday. The company reported ($2.14) EPS for the quarter, Zacks reports. Yarrow Bioscience had a negative return on equity of 79.83% and a negative net margin of 4,726.21%.

Yarrow Bioscience Price Performance

Shares of YARW stock traded down $0.23 during mid-day trading on Friday, hitting $42.49. The company’s stock had a trading volume of 5,217 shares, compared to its average volume of 31,558. Yarrow Bioscience has a 52-week low of $14.02 and a 52-week high of $46.95. The stock has a market capitalization of $28.47 million, a P/E ratio of -2.24 and a beta of 1.96.

Analysts Set New Price Targets

Several brokerages have issued reports on YARW. BTIG Research initiated coverage on shares of Yarrow Bioscience in a research report on Monday, August 3rd. They set a “buy” rating and a $58.00 target price for the company. TD Cowen began coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $58.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.